na na na na na sialic acid binding iglike lectin transmembrane receptor expressed cells myeloid usually considered myeloidspecific also found lymphoid binds sialic acids therefore member siglec family lectins extracellular portion receptor contains two immunoglobulin domains one igv one domain placing within immunoglobulin superfamily intracellular portion contains immunoreceptor tyrosinebased inhibitory motifs itims implicated inhibition cellular stimulated molecule sialic acid residues glycoproteins glycolipids upon binding immunoreceptor tyrosinebased inhibition motif itim present cytosolic portion protein phosphorylated acts docking site src homology domaincontaining proteins like shp phosphatases results cascade inhibits phagocytosis controls microglial activation alzheimer disease goes overdrive presence amyloid tau proteins expression known tied target gemtuzumab ozogamicin trade name pfizerwyethayerst antibodydrug conjugate adc treatment patients acute myeloid leukemia drug recombinant humanized monoclonal antibody κ antibody covalently attached cytotoxic antitumor antibiotic calicheamicin nacetylγcalicheamicin via bifunctional linker several mechanisms resistance gemtuzumab ozogamicin september fda approved pfizers gemtuzumab ozogamicin initially approved us food drug administration however post marketing clinical trials researchers noticed greater number deaths group patients received gemtuzumab ozogamicin compared receiving chemotherapy alone based results pfizer voluntarily withdrew gemtuzumab ozogamicin market reintroduced market also target vadastuximab talirine novel antibodydrug conjugate developed seattle genetics utilizing companys adc